Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001714899-24-000206
Filing Date
2024-10-22
Accepted
2024-10-22 16:30:57
Documents
1
Period of Report
2024-10-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1729629050.html 4  
1 FORM 4 wk-form4_1729629050.xml 4 8545
  Complete submission text file 0001714899-24-000206.txt   10047
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BLVD., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Watts Ryan J. (Reporting) CIK: 0001724310 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38311 | Film No.: 241386669